Identification

Name
Pemetrexed
Accession Number
DB00642  (APRD00573, EXPT02075)
Type
Small Molecule
Groups
Approved, Investigational
Description

Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma as well as non-small cell lung cancer.

Structure
Thumb
Synonyms
Not Available
External IDs
LY-231514 / LY231514 / NSC-698037
Product Ingredients
IngredientUNIICASInChI Key
Pemetrexed disodium2PKU919BA9150399-23-8NYDXNILOWQXUOF-GXKRWWSZSA-L
Pemetrexed disodium hemipentahydrateF4GSH45R4C357166-30-4ZCTCZKWJFTYNMZ-WKUCUCPSSA-J
Pemetrexed disodium heptahydrate9T47E4OM16357166-29-1QJVSMHJWAOSBMD-MYXYZBIASA-L
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act PemetrexedPowder, for solution1000 mgIntravenousActavis Pharma CompanyNot applicableNot applicableCanada
Act PemetrexedPowder, for solution500 mgIntravenousActavis Pharma CompanyNot applicableNot applicableCanada
Act PemetrexedPowder, for solution100 mgIntravenousActavis Pharma CompanyNot applicableNot applicableCanada
AlimtaInjection, powder, lyophilized, for solution500 mg/20mLIntravenousEli Lilly & Co. Ltd.2004-02-04Not applicableUs
AlimtaPowder, for solution500 mgIntravenousEli Lilly & Co. Ltd.2004-08-03Not applicableCanada
AlimtaInjection, powder, for solution100 mgIntravenousEli Lilly Nederland B.V.2004-09-20Not applicableEu
AlimtaInjection, powder, for solution500 mgIntravenousEli Lilly Nederland B.V.2004-09-20Not applicableEu
AlimtaInjection, powder, lyophilized, for solution100 mg/4mLIntravenousEli Lilly & Co. Ltd.2007-09-07Not applicableUs
AlimtaPowder, for solution100 mgIntravenousEli Lilly & Co. Ltd.2009-01-09Not applicableCanada
PemetrexedPowder, for solution500 mgIntravenousApotex CorporationNot applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CiambraInjection, powder, for solution500 mgIntravenousMenarini International Operations Luxembourg S.A.2015-12-02Not applicableEu
CiambraInjection, powder, for solution100 mgIntravenousMenarini International Operations Luxembourg S.A.2015-12-02Not applicableEu
Pemetrexed Accord Solution for InfusionPowder, for solution1000 mgIntravenousAccord Healthcare Limited2016-01-18Not applicableEu
Pemetrexed HospiraInjection, powder, for solution500 mgIntravenousHospira, Inc.2015-11-20Not applicableEu
Pemetrexed HospiraInjection, powder, for solution100 mgIntravenousHospira, Inc.2015-11-20Not applicableEu
Pemetrexed HospiraInjection, powder, for solution000 mgIntravenousHospira, Inc.2015-11-20Not applicableEu
Pemetrexed LillyInjection, powder, for solution500 mgIntravenousEli Lilly Netherlands2015-09-14Not applicableEu
Pemetrexed LillyInjection, powder, for solution100 mgIntravenousEli Lilly Netherlands2015-09-14Not applicableEu
Pemetrexed MedacInjection, powder, for solution500 mgIntravenousMedac Gesellschaft Für Klinische Spezialpräparate Mb H2015-11-27Not applicableEu
Pemetrexed MedacInjection, powder, for solution100 mgIntravenousMedac Gesellschaft Für Klinische Spezialpräparate Mb H2015-11-27Not applicableEu
Categories
UNII
04Q9AIZ7NO
CAS number
137281-23-3
Weight
Average: 427.4106
Monoisotopic: 427.149183429
Chemical Formula
C20H21N5O6
InChI Key
WBXPDJSOTKVWSJ-ZDUSSCGKSA-N
InChI
InChI=1S/C20H21N5O6/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29)/t13-/m0/s1
IUPAC Name
(2S)-2-{[4-(2-{4-hydroxy-2-imino-1H,2H,7H-pyrrolo[2,3-d]pyrimidin-5-yl}ethyl)phenyl]formamido}pentanedioic acid
SMILES
[H][[email protected]@](CCC(O)=O)(NC(=O)C1=CC=C(CCC2=CNC3=C2C(O)=NC(=N)N3)C=C1)C(O)=O

Pharmacology

Indication

Used in combination with cisplatin for the treatment of malignant pleural mesothelioma in adults whose disease is unresectable or who otherwise are not candidates for potentially curative surgery. Also used as a monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy

Structured Indications
Pharmacodynamics

Preclinical studies have shown that pemetrexed inhibits the in vitro growth of mesothelioma cell lines (MSTO-211H, NCI-H2052). Studies with the MSTO-211H mesothelioma cell line showed synergistic effects when pemetrexed was combined concurrently with cisplatin.

Mechanism of action

Pemetrexed is an antifolate containing the pyrrolopyrimidine-based nucleus that exerts its antineoplastic activity by disrupting folate-dependent metabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), all folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is transported into cells by both the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT. Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, to a lesser extent, in normal tissues. Polyglutamated metabolites have an increased intracellular half-life resulting in prolonged drug action in malignant cells.

TargetActionsOrganism
AThymidylate synthase
inhibitor
Human
ABifunctional purine biosynthesis protein PURH
inhibitor
Human
ADihydrofolate reductase
inhibitor
Human
ATrifunctional purine biosynthetic protein adenosine-3
inhibitor
Human
Absorption
Not Available
Volume of distribution
  • 16.1 L
Protein binding

81%

Metabolism

Metabolized by Cytochrome P450 Enzymes

Route of elimination

Pemetrexed is not metabolized to an appreciable extent and is primarily eliminated in the urine, with 70% to 90% of the dose recovered unchanged within the first 24 hours following administration.

Half life

3.5 hours

Clearance
  • 91.8 mL/min [Cancer patients with normal renal function receiving 0.2 to 838 mg/m2 infusion over a 10-minute period]
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Pemetrexed.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Pemetrexed.Experimental
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Pemetrexed.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Pemetrexed.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pemetrexed.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pemetrexed.Approved
ClozapineThe risk or severity of adverse effects can be increased when Pemetrexed is combined with Clozapine.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pemetrexed.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Pemetrexed.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Pemetrexed.Experimental
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Pemetrexed.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Pemetrexed.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Pemetrexed.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Pemetrexed.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Pemetrexed.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pemetrexed.Approved, Investigational
FingolimodPemetrexed may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Pemetrexed.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Pemetrexed.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Pemetrexed.Experimental
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Pemetrexed.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Pemetrexed.Approved, Withdrawn
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Pemetrexed.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Pemetrexed.Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Pemetrexed.Experimental
LeflunomideThe risk or severity of adverse effects can be increased when Pemetrexed is combined with Leflunomide.Approved, Investigational
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Pemetrexed.Investigational, Withdrawn
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Pemetrexed.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Pemetrexed is combined with Natalizumab.Approved, Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Pemetrexed.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Pemetrexed.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pemetrexed.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Pemetrexed.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pemetrexed.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Pemetrexed.Experimental
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Pemetrexed is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Pemetrexed.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Pemetrexed.Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Pemetrexed.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Pemetrexed.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Pemetrexed.Approved
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Pemetrexed.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pemetrexed.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Pemetrexed.Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Pemetrexed.Approved, Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Pemetrexed.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Pemetrexed.Investigational
TofacitinibPemetrexed may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Pemetrexed.Approved, Investigational
Varicella Zoster Vaccine (Live/Attenuated)The therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Pemetrexed.Approved
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Pemetrexed.Approved
Food Interactions
Not Available

References

Synthesis Reference
US5344932
General References
  1. Rollins KD, Lindley C: Pemetrexed: a multitargeted antifolate. Clin Ther. 2005 Sep;27(9):1343-82. [PubMed:16291410]
  2. Lansiaux A, Lokiec F: [Pemetrexed: from preclinic to clinic]. Bull Cancer. 2007;94 Spec No Actualites:S134-8. [PubMed:17845983]
  3. Fuld AD, Dragnev KH, Rigas JR: Pemetrexed in advanced non-small-cell lung cancer. Expert Opin Pharmacother. 2010 Jun;11(8):1387-402. doi: 10.1517/14656566.2010.482560. [PubMed:20446853]
  4. Adjei AA: Pemetrexed (Alimta): a novel multitargeted antifolate agent. Expert Rev Anticancer Ther. 2003 Apr;3(2):145-56. [PubMed:12722874]
External Links
KEGG Drug
D07472
PubChem Compound
446556
PubChem Substance
46505640
ChemSpider
393879
BindingDB
18796
ChEBI
63616
ChEMBL
CHEMBL225072
Therapeutic Targets Database
DCL000320
PharmGKB
PA10810
HET
LYA
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Pemetrexed
ATC Codes
L01BA04 — Pemetrexed
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
PDB Entries
1ju6 / 1juj / 2x9g / 3k2h / 4fqs / 4kn2 / 4lvy
FDA label
Download (233 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentBrain and Central Nervous System Tumors / Chronic Myeloproliferative Disorders / Leukemias / Lymphoproliferative Disorders / Malignant Lymphomas / Metastatic Cancers / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Precancerous Conditions / Secondary Myelofibrosis / Unspecified Adult Solid Tumor, Protocol Specific1
0RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1Active Not RecruitingTreatmentAdenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Recurrent Non-small Cell Lung Cancer / Squamous Cell Carcinoma of Lung / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer1
1Active Not RecruitingTreatmentAdvanced Cancers1
1Active Not RecruitingTreatmentAdvanced Malignancies / Cancer, Advanced1
1Active Not RecruitingTreatmentCancers1
1Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)3
1Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Tumors, Solid1
1Active Not RecruitingTreatmentMalignant Pleural Mesothelioma (MPM)1
1Active Not RecruitingTreatmentRecurrent Non-small Cell Lung Cancer / Squamous Cell Carcinoma of Lung / Stage IV Non-Small Cell Lung Cancer1
1Active Not RecruitingTreatmentStage IV Non-Small Cell Lung Cancer1
1Active Not RecruitingTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentAdvanced Non-Small Cell Lung Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC)1
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentAdvanced Solid Tumours / Cancers / Lung Cancer Non-Small Cell Cancer (NSCLC)1
1CompletedTreatmentCancer, Advanced2
1CompletedTreatmentCancer, Breast / Cancer, Ovarian / Esophageal Cancers / Head and Neck Carcinoma / Lung Cancers / Malignant Neoplasm of Stomach / Prostate Cancer1
1CompletedTreatmentCancer, Breast / Colorectal Cancers / Head and Neck Carcinoma / Lung Cancers / Malignant Neoplasm of Pancreas / Mesothelioma / Prostate Cancer / Sarcomas1
1CompletedTreatmentCancer, Ovarian / Cervical Cancers / Endometrial Cancers / Lung Cancers1
1CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
1CompletedTreatmentCancers4
1CompletedTreatmentCancers / Metastases1
1CompletedTreatmentCarcinoma NOS / Lung Cancers / Non-Small Cell Lung1
1CompletedTreatmentCentral Nervous System Lymphoma1
1CompletedTreatmentEsophageal Cancers1
1CompletedTreatmentHead and Neck Carcinoma2
1CompletedTreatmentInoperable Non Small Cell Lung Cancer1
1CompletedTreatmentLocally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV1
1CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)6
1CompletedTreatmentMalignant Lymphomas / Tumors, Solid1
1CompletedTreatmentMesothelioma2
1CompletedTreatmentNeoplasms4
1CompletedTreatmentNeoplasms, Malignant1
1CompletedTreatmentNon-Squamous Non-Small Cell Lung Cancer1
1CompletedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
1CompletedTreatmentSolid Cancers1
1CompletedTreatmentTumors, Solid2
1CompletedTreatmentUnspecified Adult Solid Tumor1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific4
1CompletedTreatmentUnspecified Childhood Solid Tumor, Protocol Specific1
1Not Yet RecruitingTreatmentCarcinoma of the Lungs / Lungcancer1
1RecruitingOtherMesothelioma1
1RecruitingTreatmentAdvanced Cancers1
1RecruitingTreatmentAdvanced Non-Small Cell Lung Cancer / KRAS Gene Mutation / Lung Cancers1
1RecruitingTreatmentBiphasic Mesothelioma / Epithelioid Mesothelioma / Stage I Pleural Malignant Mesothelioma AJCC v7 / Stage IA Pleural Malignant Mesothelioma AJCC v7 / Stage IB Pleural Malignant Mesothelioma AJCC v7 / Stage II Pleural Malignant Mesothelioma AJCC v7 / Stage III Pleural Malignant Mesothelioma AJCC v71
1RecruitingTreatmentAdvanced thymic carcinoma / Bladder Cancers / Cancer, Ovarian / Lung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Peritoneal Neoplasm / Mesothelioma / Thymus Cancer / Uterine Cervical Cancer1
1RecruitingTreatmentCancer, Advanced / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers / Metastatic Lung Cancer / Non-Squamous Non-Small Cell Neoplasm of Lung / Squamous Cell Carcinoma of Lung1
1RecruitingTreatmentCancer, Advanced / Lung Cancer Non-Small Cell Cancer (NSCLC) / Mesothelioma, Malignant / Metastatic Breast Cancer (MBC) / Metastatic Cancers / Non-Hodgkin's Lymphoma (NHL)1
1RecruitingTreatmentCancer, Breast / Colorectal Cancers / Esophagogastric Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Neoplasm of Pancreas / Tumors1
1RecruitingTreatmentCancer, Breast / Neoplasms Metastasis / Neoplasms, Colorectal1
1RecruitingTreatmentHead and Neck Carcinoma / Salivary Gland Tumors1
1RecruitingTreatmentLeptomeningeal Metastases1
1RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)3
1RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasms1
1RecruitingTreatmentMetastatic Malignant Neoplasm in the Brain / Stage IIIA Large Cell Lung Carcinoma / Stage IIIA Large Cell Lung Carcinoma AJCC v7 / Stage IIIA Lung Adenocarcinoma / Stage IIIA Lung Adenocarcinoma AJCC v7 / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer AJCC v7 / Stage IIIB Large Cell Lung Carcinoma / Stage IIIB Large Cell Lung Carcinoma AJCC v7 / Stage IIIB Lung Adenocarcinoma / Stage IIIB Lung Adenocarcinoma AJCC v7 / Stage IIIb Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer AJCC v7 / Stage IV Large Cell Lung Carcinoma / Stage IV Large Cell Lung Carcinoma AJCC v7 / Stage IV Lung Adenocarcinoma / Stage IV Lung Adenocarcinoma AJCC v7 / Stage IV Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer AJCC v71
1RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
1RecruitingTreatmentOncology, Medical1
1RecruitingTreatmentPleural Mesotheliomas1
1RecruitingTreatmentStage IV Lung Adenocarcinoma1
1TerminatedTreatmentAdvanced Solid Malignancies / Cancers / Tumors, Solid1
1TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)4
1TerminatedTreatmentMalignant Lymphomas1
1TerminatedTreatmentMalignant Neoplasm of Pancreas1
1TerminatedTreatmentNonsmall Cell Lung Cancer Stage III / Nonsquamous Nonsmall Cell Neoplasm of Lung1
1WithdrawnTreatmentAdvanced Solid Tumors1
1WithdrawnTreatmentCancers / Neoplasms / Tumors1
1WithdrawnTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1WithdrawnTreatmentLung Cancers1
1WithdrawnTreatmentMalignant Pleural Mesothelioma (MPM)1
1, 2Active Not RecruitingTreatmentAdvanced Malignant Mesothelioma / Epithelioid Mesothelioma / Pleural Malignant Mesothelioma / Recurrent Malignant Mesothelioma / Sarcomatoid Mesothelioma1
1, 2Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Pleural Mesothelioma (MPM)1
1, 2Active Not RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
1, 2CompletedTreatmentAdvanced Carcinoma / Lung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2CompletedTreatmentCancer, Advanced / Lung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2CompletedTreatmentCancer, Breast1
1, 2CompletedTreatmentCancer, Ovarian / Primary Peritoneal Cancer1
1, 2CompletedTreatmentColorectal Cancers1
1, 2CompletedTreatmentExtrahepatic Bile Duct Cancer / Gallbladder Cancer / Liver Cancer1
1, 2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)7
1, 2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
1, 2CompletedTreatmentLung Cancers / Unspecified Adult Solid Tumor, Protocol Specific2
1, 2CompletedTreatmentMalignant Pleural Mesothelioma (MPM)1
1, 2CompletedTreatmentMalignant Pleural Mesothelioma (MPM) / Tumors, Solid1
1, 2CompletedTreatmentMalignant Pleural Mesotherioma1
1, 2CompletedTreatmentNeoplasm, Gastric1
1, 2CompletedTreatmentNeoplasms, Lung1
1, 2CompletedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
1, 2CompletedTreatmentRectal Carcinoma1
1, 2CompletedTreatmentTransitional Cell Carcinoma1
1, 2CompletedTreatmentUrologic Neoplasms1
1, 2RecruitingTreatmentAdvanced Malignant Solid Neoplasm / Advanced Peritoneal Malignant Mesothelioma / Advanced Pleural Malignant Mesothelioma / Advanced thymic carcinoma / Neoplasms, Advanced Solid / Recurrent Malignant Solid Neoplasm / Recurrent Peritoneal Malignant Mesothelioma / Recurrent Pleural Malignant Mesothelioma / Recurrent Solid Neoplasm / Solid Neoplasms / Stage III Non-Small Cell Lung Cancer / Stage III Non-Small Cell Lung Cancer AJCC v7 / Stage III Ovarian Cancer / Stage III Ovarian Cancer AJCC v6 and v7 / Stage III Pleural Malignant Mesothelioma AJCC v7 / Stage III Pleural Mesothelioma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer AJCC v7 / Stage IIIA Ovarian Cancer / Stage IIIA Ovarian Cancer AJCC v6 and v7 / Stage IIIb Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer AJCC v7 / Stage IIIB Ovarian Cancer / Stage IIIB Ovarian Cancer AJCC v6 and v7 / Stage IIIC Ovarian Cancer / Stage IIIC Ovarian Cancer AJCC v6 and v7 / Stage IV Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer AJCC v7 / Stage IV Ovarian Cancer / Stage IV Ovarian Cancer AJCC v6 and v7 / Stage IV Pleural Malignant Mesothelioma AJCC v7 / Stage IV Pleural Mesothelioma / Unresectable Solid Neoplasm1
1, 2RecruitingTreatmentAdvanced or Metastatic Colorectal Cancer (CRC) / Advanced or Metastatic Solid Tumor That Progressed on Previous Therapy With a Programmed Cell Death Ligand 1 (PD-L1) Inhibitor / Advanced or Metastatic Solid Tumor That Progressed on Previous Therapy With a Programmed Cell Death Protein 1 (PD-1) Inhibitor / Advanced or Metastatic Solid Tumors / Non-Small Cell Lung Cancer (NSCLC; Squamous or Nonsquamous) / Pancreatic Ductal Adenocarcinoma (PDAC)1
1, 2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)3
1, 2RecruitingTreatmentMesothelioma1
1, 2RecruitingTreatmentTo Determine Safety, Tolerability and Efficacy of ONCOS-102 in Combination With Chemotherapy1
1, 2TerminatedTreatmentCancer, Breast / Lung Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2TerminatedTreatmentCarcinoma, Small Cell / Lung Cancer Small Cell Lung Cancer (SCLC)1
1, 2TerminatedTreatmentHead and Neck Carcinoma1
1, 2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)3
1, 2TerminatedTreatmentMesothelioma1
1, 2Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
1, 2WithdrawnTreatmentMalignant Pleural Mesothelioma (MPM)1
2Active Not RecruitingTreatmentBrain and Central Nervous System Tumors / Malignant Lymphomas / Metastatic Cancers1
2Active Not RecruitingTreatmentCancers1
2Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)4
2Active Not RecruitingTreatmentLung Cancers3
2Active Not RecruitingTreatmentLung Cancers / Neoplasms Metastasis1
2Active Not RecruitingTreatmentMalignant Pleural Mesothelioma (MPM)1
2Active Not RecruitingTreatmentMesothelioma, Malignant2
2Active Not RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2Active Not RecruitingTreatmentMetastatic Colorectal Cancers1
2Active Not RecruitingTreatmentMetastatic Non-Small Cell Lung Cancer / Nonsquamous Nonsmall Cell Neoplasm of Lung1
2Active Not RecruitingTreatmentNon Small Cell Lung Carcinoma (NSCLC)1
2Active Not RecruitingTreatmentNonsquamous Nonsmall Cell Neoplasm of Lung1
2Active Not RecruitingTreatmentRecurrent Non-small Cell Lung Cancer / Recurrent Non-Small Cell Lung Carcinoma / Stage IIIb Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer AJCC v7 / Stage IV Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer AJCC v71
2Approved for MarketingNot AvailableMesothelioma1
2CompletedNot AvailableMetastatic Non-Small Cell Lung Cancer / Non-Small Cell Lung Cancer Stage IIIB / Nonsquamous Non-Small Cell Neoplasm of Lung1
2CompletedDiagnosticCancers1
2CompletedPreventionHistological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy1
2CompletedTreatmentAdenocarcinoma of Colon / Adenocarcinoma of Rectum / Metastatic Disease1
2CompletedTreatmentAdenocarcinoma of the Lung1
2CompletedTreatmentAdenocarcinoma of the Lung / Metastatic Brain Tumors1
2CompletedTreatmentAdenocarcinomas1
2CompletedTreatmentAdenocarcinomas / Lung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedTreatmentAdvanced Gastric Carcinoma1
2CompletedTreatmentAdvanced Non Small Cell Lung Cancer (NSCLC)1
2CompletedTreatmentAdvanced Non-Small Cell Lung Cancer1
2CompletedTreatmentAdvanced Non-Squamous Non-Small Cell Lung Cancer1
2CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer1
2CompletedTreatmentBreast Neoplasms, Male / Cancer, Breast / Ductal Carcinoma1
2CompletedTreatmentCancer of the Endometrium / Endometrial Cancers / Endometrial Carcinoma / Endometrium Cancer / Genital Neoplasms, Female / Genitourinary tract neoplasm / Neoplasms / Neoplasms by Site / Neoplasms, Endometrial / Uterine Neoplasms1
2CompletedTreatmentCancer, Breast6
2CompletedTreatmentCancer, Breast / Neoplasms Metastasis1
2CompletedTreatmentCancer, Breast / Neoplasms, Breast1
2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Malignant Peritoneal Neoplasm1
2CompletedTreatmentCancer, Ovarian / Malignant Peritoneal Neoplasm1
2CompletedTreatmentCancer, Ovarian / Primary Peritoneal Cavity Cancer1
2CompletedTreatmentCancers1
2CompletedTreatmentCarcinoma NOS / Lung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedTreatmentCarcinoma, Small Cell1
2CompletedTreatmentCervical Cancers2
2CompletedTreatmentCervical Intraepithelial Neoplasia (CIN) / Genital Neoplasms, Female / Uterine Neoplasms1
2CompletedTreatmentChoriocarcinoma / Hydatidiform Mole / Trophoblastic Neoplasms / Uterine Neoplasms1
2CompletedTreatmentColorectal Cancers2
2CompletedTreatmentEndometrial Cancers1
2CompletedTreatmentEpendymomas / Ewing's Sarcoma (ES) / Medulloblastomas / Neuroblastoma (Measurable Disease) / Neuroblastoma (Metaiodobenzylguanidine / Non-brainstem High-grade Glioma / Positive Evaluable) / Rhabdomyosarcomas / Sarcoma, Osteogenic1
2CompletedTreatmentHead and Neck Carcinoma4
2CompletedTreatmentHormone-Resistant Prostate Cancer / Recurrent Prostate Cancer1
2CompletedTreatmentLiver Cancer1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)39
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers2
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Mesothelioma / Neoplasms, Lung1
2CompletedTreatmentLung Cancers22
2CompletedTreatmentLung Cancers / Non Small Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentMalignant Neoplasm of Pancreas1
2CompletedTreatmentMalignant Neoplasm of Stomach2
2CompletedTreatmentMalignant Pleural Mesothelioma (MPM)2
2CompletedTreatmentMesothelioma4
2CompletedTreatmentMesothelioma, Malignant2
2CompletedTreatmentMetastatic Colorectal Cancers2
2CompletedTreatmentMetastatic Non-squamous Non Small Cell Lung Cancer1
2CompletedTreatmentNasopharyngeal Neoplasms1
2CompletedTreatmentNeoplasm Metastases / Urologic Neoplasms1
2CompletedTreatmentNeoplasms, Breast1
2CompletedTreatmentNeoplasms, Gastrointestinal1
2CompletedTreatmentNeoplasms, Head and Neck2
2CompletedTreatmentNeoplasms, Lung1
2CompletedTreatmentNeoplasms, Ovarian / Primary Peritoneal Cancer1
2CompletedTreatmentNeuroendocrine Tumors1
2CompletedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentNon-Squamous Non-Small Cell Lung Cancer2
2CompletedTreatmentOvarian Carcinoma / Primary Peritoneal Carcinoma1
2CompletedTreatmentPleural Neoplasms1
2CompletedTreatmentPrevious Treated Metastatic Non-small Cell Lung Cancer1
2CompletedTreatmentPreviously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer1
2CompletedTreatmentProstate Cancer1
2CompletedTreatmentRectal Neoplasms1
2CompletedTreatmentRecurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma1
2CompletedTreatmentRecurrent Non-small Cell Lung Cancer1
2CompletedTreatmentSarcoma, Osteogenic1
2CompletedTreatmentSarcomas2
2CompletedTreatmentSoft Tissue Sarcoma (STS)1
2CompletedTreatmentAdvanced thymic carcinoma / Thymic Carcinoma1
2CompletedTreatmentTransitional Cell Carcinoma1
2CompletedTreatmentUrologic Neoplasms1
2Not Yet RecruitingTreatmentAdenocarcinoma of the Lung1
2Not Yet RecruitingTreatmentAdvanced Non-squamous Non-small-cell Lung Cancer1
2Not Yet RecruitingTreatmentColo-rectal Cancer1
2Not Yet RecruitingTreatmentEGFR Gene Mutations / Lung Cancer Non-Small Cell Cancer (NSCLC)1
2Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)3
2Not Yet RecruitingTreatmentLung Cancers1
2Not Yet RecruitingTreatmentMalignant Pleural Mesothelioma (MPM)1
2Not Yet RecruitingTreatmentMetastatic Brain Tumors1
2Not Yet RecruitingTreatmentNon-Squamous Non-Small Cell Lung Carcinoma / Stage I Non-Small Cell Lung Cancer AJCC v7 / Stage IA Non-Small Cell Lung Carcinoma AJCC v7 / Stage IB Non-Small Cell Lung Carcinoma AJCC v7 / Stage II Non-Small Cell Lung Cancer AJCC v7 / Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 / Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 / Stage IIIA Non-Small Cell Lung Cancer AJCC v71
2RecruitingTreatmentAdenocarcinoma of the Lung1
2RecruitingTreatmentAdenocarcinomas / Carcinoma, Large Cell / Heregulin / Lung Cancer Non-Small Cell Cancer (NSCLC) / Squamous Cell Carcinoma (SCC)1
2RecruitingTreatmentAdenocarcinomas / Neoplasms, Lung1
2RecruitingTreatmentAdvanced NSCLC1
2RecruitingTreatmentAdvanced Stage IIIB / High Thymidylate Synthase Expression / Lung Cancer Non-Small Cell Cancer (NSCLC) / Secondary1
2RecruitingTreatmentBevacizumab / Metastatic Brain Tumors / Non Squamous Non-small Cell Lung Cancer1
2RecruitingTreatmentBladder Cancers / Urothelial Cancer1
2RecruitingTreatmentCancer, Breast / Metastatic Breast Cancer (MBC) / Recurrent Breast Cancer1
2RecruitingTreatmentCancers of the Head and Neck / Lung Cancer Non-Small Cell Cancer (NSCLC) / Squamous Cell Carcinoma of Esophagus / Transitional Cell Carcinoma / Urinary Bladder Neoplasms1
2RecruitingTreatmentCarcinoma, Non-squamous Non-small-cell Lung1
2RecruitingTreatmentChemotherapy, Adjuvant / Histological Type of Neoplasm / Lung Adenocarcinoma, Stage I / Treatments1
2RecruitingTreatmentColorectal Cancers1
2RecruitingTreatmentEGFR Mutations / Lung Cancer Non-Small Cell Cancer (NSCLC) / Metastatic Brain Tumors1
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)9
2RecruitingTreatmentLung Cancers2
2RecruitingTreatmentMalignant Pleural Mesothelioma (MPM)1
2RecruitingTreatmentMedulloblastomas1
2RecruitingTreatmentMesothelioma2
2RecruitingTreatmentMetastatic Non-Small Cell Lung Cancer1
2RecruitingTreatmentMetastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)1
2RecruitingTreatmentNon-small-cell Lung Cancer With Somatic EGFR Mutations1
2RecruitingTreatmentRecurrent Non-Small Cell Lung Carcinoma / Stage IV Non-Small Cell Lung Cancer1
2RecruitingTreatmentSquamous Cell Carcinoma of Lung1
2RecruitingTreatmentStage IV Non-Small Cell Lung Cancer1
2SuspendedTreatmentAdenocarcinoma of the Lung / Large Cell Lung Cancer / Recurrent Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2SuspendedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2TerminatedDiagnosticMalignant Pleural Mesothelioma (MPM) / Pleural Mesotheliomas1
2TerminatedTreatmentAdenocarcinoma of the Cervix / Adenosquamous Cell Carcinoma of the Cervix1
2TerminatedTreatmentCancer, Ovarian / Malignant Peritoneal Neoplasm1
2TerminatedTreatmentCarcinoma, Small Cell1
2TerminatedTreatmentEsophageal Cancers1
2TerminatedTreatmentGestational Trophoblastic Disease1
2TerminatedTreatmentHead and Neck Carcinoma1
2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)15
2TerminatedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)4
2TerminatedTreatmentLung Cancers6
2TerminatedTreatmentLung Cancers / Metastatic Cancers1
2TerminatedTreatmentMalignant Neoplasm of Pancreas1
2TerminatedTreatmentMesothelioma, Malignant1
2TerminatedTreatmentMesothelioma / Pleural Mesotheliomas1
2TerminatedTreatmentMetastatic Colorectal Cancers1
2TerminatedTreatmentNeoplasms, Esophageal1
2TerminatedTreatmentNeoplasms, Lung1
2TerminatedTreatmentNon Small Cell Lung Carcinoma (NSCLC)1
2TerminatedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)2
2TerminatedTreatmentNon-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer / Squamous Cell Non-Metastatic Non-Small Cell Lung Cancer1
2TerminatedTreatmentRecurrent Non Small Cell Lung Cancer1
2TerminatedTreatmentRecurrent Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2TerminatedTreatmentRenal Cell Adenocarcinoma1
2Unknown StatusTreatmentAdvanced Non-Small Cell Lung Cancer1
2Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)8
2Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Toxicity1
2Unknown StatusTreatmentMalignant / Mesothelioma / Pleural1
2Unknown StatusTreatmentPleural Mesotheliomas1
2Unknown StatusTreatmentSquamous Cell Carcinoma of Head and Neck1
2Unknown StatusTreatmentThyroid Cancers1
2Unknown StatusTreatmentTumors, Central Nervous System1
2Unknown StatusTreatmentUntreated Advanced Non-Small Cell Lung Cancer1
2WithdrawnDiagnosticStage IIIA Non-Small Cell Lung Cancer1
2WithdrawnTreatmentAdvanced Malignant Mesothelioma / Epithelial Mesothelioma / Recurrent Malignant Mesothelioma / Sarcomatous Mesothelioma1
2WithdrawnTreatmentCancer of Head and Neck1
2WithdrawnTreatmentEsophagogastric Cancer1
2WithdrawnTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
2WithdrawnTreatmentPrimary Central Nervous System Lymphoma (PCNSL)1
2WithdrawnTreatmentRecurrent Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2WithdrawnTreatmentStage III Non-Small Cell Lung Cancer1
2, 3Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non-Small Cell Lung Cancer Recurrent / Progression of Non-small Cell Lung Cancer1
2, 3CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2, 3CompletedTreatmentMesothelioma1
2, 3RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2, 3RecruitingTreatmentMesothelioma1
2, 3TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3Active Not RecruitingPreventionLung Cancer Non-Small Cell Cancer (NSCLC)1
3Active Not RecruitingTreatmentAdenocarcinomas / Lung Cancer Non-Small Cell Cancer (NSCLC)1
3Active Not RecruitingTreatmentAdvanced Non Small Cell Lung Cancer1
3Active Not RecruitingTreatmentAdvanced Non-Small Cell Lung Cancer1
3Active Not RecruitingTreatmentAnaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC)1
3Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)7
3Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
3Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non-Small Cell Lung Carcinoma (NSCLC)1
3Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non-Small-Cell Lung Carcinoma NSCLC1
3Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non-Squamous Non-Small Cell Lung Cancer1
3Active Not RecruitingTreatmentLung Cancers1
3Active Not RecruitingTreatmentMetastatic Non-Small Cell Lung Cancer / Non-Small Cell Lung Cancer Stage IIIB1
3Active Not RecruitingTreatmentNon Small Cell Lung Cancer (Squamous or Non Squamous)1
3Active Not RecruitingTreatmentNon-Squamous Non-Small Cell Lung Cancer1
3Active Not RecruitingTreatmentStage IB Non-Small Cell Lung Carcinoma / Stage IB Non-Small Cell Lung Carcinoma AJCC v7 / Stage IIA Non-Small Cell Lung Carcinoma / Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 / Stage IIB Non-Small Cell Lung Carcinoma / Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer AJCC v71
3Active Not RecruitingTreatmentStage IV or Recurrent Non-Small Cell Lung Cancer1
3CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)14
3CompletedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
3CompletedTreatmentLung Cancers1
3CompletedTreatmentMesothelioma1
3CompletedTreatmentMesothelioma, Malignant1
3CompletedTreatmentNeoplasm Metastases / Neoplasms, Pancreatic1
3CompletedTreatmentNeoplasms, Head and Neck1
3CompletedTreatmentNon Small Cell Lung Carcinoma (NSCLC)2
3CompletedTreatmentNon-Squamous Non-Small Cell Lung Cancer3
3Enrolling by InvitationTreatmentCancers1
3Enrolling by InvitationTreatmentEGFR Gene Mutations1
3Not Yet RecruitingTreatmentCarcinoma, Bronchogenic / Chronic Lung Diseases / Lung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasm, Bronchial / Neoplasms by Site / Neoplasms, Lung / Respiratory Tract Diseases / Respiratory Tract Neoplasms / Thoracic Neoplasms1
3Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)3
3Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Hydrothorax1
3RecruitingOtherAdenocarcinoma of Lung Metastatic to Brain / Bevacizumab / Brain Radiotherapy / Cerebral Metastases / Cerebral Radiotherapy / Lung Cancer Non-Small Cell Cancer (NSCLC) / Metastatic Non-Small Cell Lung Cancer / Non Epidermoid1
3RecruitingTreatmentBladder Cancers / Transitional Cell Carcinoma / Ureteral Cancer1
3RecruitingTreatmentCarcinoma,Non-Small-Cell Lung1
3RecruitingTreatmentCarcinoma,Non-Small-Cell Lung / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Carcinomas, Non-Small-Cell1
3RecruitingTreatmentChemotherapeutic Toxicity / Chemotherapy Effect / Stomach Neoplasms1
3RecruitingTreatmentFirst Line Non-Small Cell Lung Cancer1
3RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)10
3RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Metastatic Non-Squamous Non-Small Cell Lung Cancer1
3RecruitingTreatmentMesothelioma2
3RecruitingTreatmentNeoplasms, Lung1
3RecruitingTreatmentNon Small Cell Lung Carcinoma (NSCLC) / Non Small Cell Lung Carcinoma NSCLC2
3RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
3RecruitingTreatmentNon-Squamous Non-Small Cell Lung Cancer / Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer1
3RecruitingTreatmentOligo-metastatic Stage IV Non-small Cell Lung Cancer / Oligo-metastatic Stage IV Non-small Cell Lung Cancer(NSCLC)1
3TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers / Neoplasms, Lung / Pulmonary Neoplasms1
3TerminatedTreatmentLung Cancers1
3TerminatedTreatmentNon Small Cell Lung Carcinoma (NSCLC)1
3TerminatedTreatmentRecurrent Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
3Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3Unknown StatusTreatmentLung Cancers1
3Unknown StatusTreatmentNon-squamous Nonsmall Cell Neoplasm of Lung1
4CompletedTreatmentLocally Advanced Malignant Neoplasm1
4CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)3
4Not Yet RecruitingTreatmentAdenocarcinoma of the Lung1
4RecruitingTreatmentAdenocarcinoma of the Lung1
4RecruitingTreatmentAdenocarcinomas / EGFR Positive Non-small Cell Lung Cancer2
4RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
Not AvailableCompletedNot AvailableLung Cancer Non-Small Cell Cancer (NSCLC)1
Not AvailableCompletedNot AvailableNeoplasms, Lung1
Not AvailableCompletedTreatmentHypermethylation / Lung Cancers / Non Small Cell Lung Carcinoma (NSCLC)1
Not AvailableCompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
Not AvailableTerminatedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
Not AvailableUnknown StatusScreeningLung Cancer Non-Small Cell Cancer (NSCLC)1
Not AvailableUnknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1

Pharmacoeconomics

Manufacturers
  • Eli lilly and co
Packagers
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntravenous100 mg/4mL
Injection, powder, lyophilized, for solutionIntravenous500 mg/20mL
Powder, for solutionIntravenous100 mg
Powder, for solutionIntravenous500 mg
Injection, powder, for solutionIntravenous100 mg
Injection, powder, for solutionIntravenous500 mg
Powder, for solutionIntravenous1000 mg
Injection, powder, for solutionIntravenous000 mg
Injection, powder, for solutionIntravenous1000 mg
Prices
Unit descriptionCostUnit
Alimta 500 mg Solution Vial3154.94USD vial
Alimta 500 mg vial3033.6USD vial
Alimta 100 mg vial606.72USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5217974No1994-03-292011-03-29Us
CA2400155No2009-09-152021-02-12Canada
CA1340794No1999-10-192016-10-19Canada
US7772209Yes2002-05-242022-05-24Us
US5344932Yes1997-01-242017-01-24Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP-1.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0905 mg/mLALOGPS
logP-0.19ALOGPS
logP-0.25ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)3.34ChemAxon
pKa (Strongest Basic)7.13ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count7ChemAxon
Polar Surface Area187.96 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity120.46 m3·mol-1ChemAxon
Polarizability43.06 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.6997
Blood Brain Barrier+0.7542
Caco-2 permeable-0.819
P-glycoprotein substrateSubstrate0.5
P-glycoprotein inhibitor INon-inhibitor0.9729
P-glycoprotein inhibitor IINon-inhibitor0.9825
Renal organic cation transporterNon-inhibitor0.8923
CYP450 2C9 substrateNon-substrate0.7547
CYP450 2D6 substrateNon-substrate0.8204
CYP450 3A4 substrateNon-substrate0.6051
CYP450 1A2 substrateNon-inhibitor0.912
CYP450 2C9 inhibitorNon-inhibitor0.8938
CYP450 2D6 inhibitorNon-inhibitor0.9117
CYP450 2C19 inhibitorNon-inhibitor0.8844
CYP450 3A4 inhibitorNon-inhibitor0.8253
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9508
Ames testNon AMES toxic0.8528
CarcinogenicityNon-carcinogens0.964
BiodegradationNot ready biodegradable0.8296
Rat acute toxicity2.5023 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9624
hERG inhibition (predictor II)Non-inhibitor0.8718
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as glutamic acid and derivatives. These are compounds containing glutamic acid or a derivative thereof resulting from reaction of glutamic acid at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Glutamic acid and derivatives
Alternative Parents
N-acyl-alpha amino acids / Hippuric acids / Pyrrolo[2,3-d]pyrimidines / Benzoyl derivatives / Pyrimidones / Aminopyrimidines and derivatives / Substituted pyrroles / Dicarboxylic acids and derivatives / Vinylogous amides / Heteroaromatic compounds
show 9 more
Substituents
Glutamic acid or derivatives / Hippuric acid or derivatives / Hippuric acid / N-acyl-alpha-amino acid / N-acyl-alpha amino acid or derivatives / Pyrrolopyrimidine / Benzamide / Pyrrolo[2,3-d]pyrimidine / Benzoic acid or derivatives / Benzoyl
show 27 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
pyrrolopyrimidine, N-acyl-L-glutamic acid (CHEBI:63616)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Thymidylate synthase activity
Specific Function
Contributes to the de novo mitochondrial thymidylate biosynthesis pathway.
Gene Name
TYMS
Uniprot ID
P04818
Uniprot Name
Thymidylate synthase
Molecular Weight
35715.65 Da
References
  1. Adjei AA: Gemcitabine and Pemetrexed disodium in treating breast cancer. Oncology (Williston Park). 2001 Feb;15(2 Suppl 3):34-7. [PubMed:11252887]
  2. Hanauske AR, Chen V, Paoletti P, Niyikiza C: Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist. 2001;6(4):363-73. [PubMed:11524555]
  3. Pivot X, Raymond E, Laguerre B, Degardin M, Cals L, Armand JP, Lefebvre JL, Gedouin D, Ripoche V, Kayitalire L, Niyikiza C, Johnson R, Latz J, Schneider M: Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer. 2001 Sep 1;85(5):649-55. [PubMed:11531245]
  4. Adjei AA: Gemcitabine and pemetrexed disodium combinations in vitro and in vivo. Lung Cancer. 2001 Dec;34 Suppl 4:S103-5. [PubMed:11742712]
  5. Norman P: Pemetrexed disodium (Eli Lilly). Curr Opin Investig Drugs. 2001 Nov;2(11):1611-22. [PubMed:11763166]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Schultz RM, Dempsey JA: Sequence dependence of Alimta (LY231514, MTA) combined with doxorubicin in ZR-75-1 human breast carcinoma cells. Anticancer Res. 2001 Sep-Oct;21(5):3209-14. [PubMed:11848474]
  8. Adjei AA: Pemetrexed in the treatment of selected solid tumors. Semin Oncol. 2002 Apr;29(2 Suppl 5):50-3. [PubMed:12023793]
  9. Molina JR, Adjei AA: The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy. Clin Lung Cancer. 2003 Jul;5(1):21-7. [PubMed:14596699]
  10. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, Danesi R: Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol. 2005 Jul;68(1):110-8. Epub 2005 Mar 28. [PubMed:15795320]
  11. Kindler HL: Pemetrexed in pancreatic cancer. Semin Oncol. 2002 Dec;29(6 Suppl 18):49-53. [PubMed:12571811]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Protein homodimerization activity
Specific Function
Bifunctional enzyme that catalyzes 2 steps in purine biosynthesis.Promotes insulin receptor/INSR autophosphorylation and is involved in INSR internalization (PubMed:25687571).
Gene Name
ATIC
Uniprot ID
P31939
Uniprot Name
Bifunctional purine biosynthesis protein PURH
Molecular Weight
64615.255 Da
References
  1. Kindler HL: Pemetrexed in pancreatic cancer. Semin Oncol. 2002 Dec;29(6 Suppl 18):49-53. [PubMed:12571811]
  2. Hanauske AR, Chen V, Paoletti P, Niyikiza C: Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist. 2001;6(4):363-73. [PubMed:11524555]
  3. Racanelli AC, Rothbart SB, Heyer CL, Moran RG: Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res. 2009 Jul 1;69(13):5467-74. doi: 10.1158/0008-5472.CAN-08-4979. Epub 2009 Jun 23. [PubMed:19549896]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Nadph binding
Specific Function
Key enzyme in folate metabolism. Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA pre...
Gene Name
DHFR
Uniprot ID
P00374
Uniprot Name
Dihydrofolate reductase
Molecular Weight
21452.61 Da
References
  1. Hanauske AR, Chen V, Paoletti P, Niyikiza C: Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist. 2001;6(4):363-73. [PubMed:11524555]
  2. Norman P: Pemetrexed disodium (Eli Lilly). Curr Opin Investig Drugs. 2001 Nov;2(11):1611-22. [PubMed:11763166]
  3. Mauritz R, Peters GJ, Priest DG, Assaraf YG, Drori S, Kathmann I, Noordhuis P, Bunni MA, Rosowsky A, Schornagel JH, Pinedo HM, Jansen G: Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis. Biochem Pharmacol. 2002 Jan 15;63(2):105-15. [PubMed:11841783]
  4. Schultz RM, Dempsey JA: Sequence dependence of Alimta (LY231514, MTA) combined with doxorubicin in ZR-75-1 human breast carcinoma cells. Anticancer Res. 2001 Sep-Oct;21(5):3209-14. [PubMed:11848474]
  5. Adjei AA: Pemetrexed in the treatment of selected solid tumors. Semin Oncol. 2002 Apr;29(2 Suppl 5):50-3. [PubMed:12023793]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Adjei AA: Gemcitabine and Pemetrexed disodium in treating breast cancer. Oncology (Williston Park). 2001 Feb;15(2 Suppl 3):34-7. [PubMed:11252887]
  8. Pivot X, Raymond E, Laguerre B, Degardin M, Cals L, Armand JP, Lefebvre JL, Gedouin D, Ripoche V, Kayitalire L, Niyikiza C, Johnson R, Latz J, Schneider M: Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer. 2001 Sep 1;85(5):649-55. [PubMed:11531245]
  9. Adjei AA: Gemcitabine and pemetrexed disodium combinations in vitro and in vivo. Lung Cancer. 2001 Dec;34 Suppl 4:S103-5. [PubMed:11742712]
  10. Molina JR, Adjei AA: The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy. Clin Lung Cancer. 2003 Jul;5(1):21-7. [PubMed:14596699]
  11. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, Danesi R: Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol. 2005 Jul;68(1):110-8. Epub 2005 Mar 28. [PubMed:15795320]
  12. Kindler HL: Pemetrexed in pancreatic cancer. Semin Oncol. 2002 Dec;29(6 Suppl 18):49-53. [PubMed:12571811]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Phosphoribosylglycinamide formyltransferase activity
Specific Function
Not Available
Gene Name
GART
Uniprot ID
P22102
Uniprot Name
Trifunctional purine biosynthetic protein adenosine-3
Molecular Weight
107766.295 Da
References
  1. Schultz RM, Dempsey JA: Sequence dependence of Alimta (LY231514, MTA) combined with doxorubicin in ZR-75-1 human breast carcinoma cells. Anticancer Res. 2001 Sep-Oct;21(5):3209-14. [PubMed:11848474]
  2. Hanauske AR, Chen V, Paoletti P, Niyikiza C: Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist. 2001;6(4):363-73. [PubMed:11524555]
  3. Molina JR, Adjei AA: The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy. Clin Lung Cancer. 2003 Jul;5(1):21-7. [PubMed:14596699]
  4. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, Danesi R: Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol. 2005 Jul;68(1):110-8. Epub 2005 Mar 28. [PubMed:15795320]
  5. Kindler HL: Pemetrexed in pancreatic cancer. Semin Oncol. 2002 Dec;29(6 Suppl 18):49-53. [PubMed:12571811]
  6. Adjei AA: Gemcitabine and Pemetrexed disodium in treating breast cancer. Oncology (Williston Park). 2001 Feb;15(2 Suppl 3):34-7. [PubMed:11252887]
  7. Pivot X, Raymond E, Laguerre B, Degardin M, Cals L, Armand JP, Lefebvre JL, Gedouin D, Ripoche V, Kayitalire L, Niyikiza C, Johnson R, Latz J, Schneider M: Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer. 2001 Sep 1;85(5):649-55. [PubMed:11531245]
  8. Adjei AA: Gemcitabine and pemetrexed disodium combinations in vitro and in vivo. Lung Cancer. 2001 Dec;34 Suppl 4:S103-5. [PubMed:11742712]
  9. Adjei AA: Pemetrexed in the treatment of selected solid tumors. Semin Oncol. 2002 Apr;29(2 Suppl 5):50-3. [PubMed:12023793]
  10. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Protein homodimerization activity
Specific Function
Required for the phosphorylation of the deoxyribonucleosides deoxycytidine (dC), deoxyguanosine (dG) and deoxyadenosine (dA). Has broad substrate specificity, and does not display selectivity based...
Gene Name
DCK
Uniprot ID
P27707
Uniprot Name
Deoxycytidine kinase
Molecular Weight
30518.315 Da
References
  1. De Pas TM, Toffalorio F, Giovannetti E, Radice D, Russo F, Angeli I, Calamai G, Spitaleri G, Catania C, Noberasco C, Milani A, Pelosi G, Danesi R, De Braud F: Optimizing pemetrexed-gemcitabine combination in patients with advanced non-small cell lung cancer: a pharmacogenetic approach. J Thorac Oncol. 2011 Apr;6(4):768-73. doi: 10.1097/JTO.0b013e31820d7818. [PubMed:21336182]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Nucleoside transmembrane transporter activity
Specific Function
Mediates both influx and efflux of nucleosides across the membrane (equilibrative transporter). It is sensitive (ES) to low concentrations of the inhibitor nitrobenzylmercaptopurine riboside (NBMPR...
Gene Name
SLC29A1
Uniprot ID
Q99808
Uniprot Name
Equilibrative nucleoside transporter 1
Molecular Weight
50218.805 Da
References
  1. De Pas TM, Toffalorio F, Giovannetti E, Radice D, Russo F, Angeli I, Calamai G, Spitaleri G, Catania C, Noberasco C, Milani A, Pelosi G, Danesi R, De Braud F: Optimizing pemetrexed-gemcitabine combination in patients with advanced non-small cell lung cancer: a pharmacogenetic approach. J Thorac Oncol. 2011 Apr;6(4):768-73. doi: 10.1097/JTO.0b013e31820d7818. [PubMed:21336182]

Drug created on June 13, 2005 07:24 / Updated on December 15, 2017 13:48